中国医药指南
中國醫藥指南
중국의약지남
CHINA MEDICINE GUIDE
2013年
2期
8-9
,共2页
Graves’病%细胞因子%131I
Graves’病%細胞因子%131I
Graves’병%세포인자%131I
Graves’Disease%Cytokines%131I
目的通过对131I治疗前后Graves’病患者血清IL-2、IL-6和TNF-α细胞因子水平的比较,探讨细胞因子与Graves病发生、发展的内在联系.方法放射免疫分析法检测45例接受131I治疗的GD患者治疗前后60d外周血清IL-2、IL-6和TNF-α浓度变化,分析其与血清甲状腺激素水平的相关性分析.GD患者治疗前血清IL-6,TNF-α水平显著高于对照组(P<0.01),131I治疗后IL-6,TNF-α水平明显降低.而IL-2治疗前显著降低,治疗后逐渐回升(P<0.01);血清IL-6、TNF-α水平与FT3、FT4呈明显正相关(P<0.05),而IL-2与FT3、FT4明显负相关.结论131I治疗Graves’病不仅可以安全有效地控制甲亢症状且可改善自身免疫紊乱,多种细胞因子的变化和131I治疗的效果有关.
目的通過對131I治療前後Graves’病患者血清IL-2、IL-6和TNF-α細胞因子水平的比較,探討細胞因子與Graves病髮生、髮展的內在聯繫.方法放射免疫分析法檢測45例接受131I治療的GD患者治療前後60d外週血清IL-2、IL-6和TNF-α濃度變化,分析其與血清甲狀腺激素水平的相關性分析.GD患者治療前血清IL-6,TNF-α水平顯著高于對照組(P<0.01),131I治療後IL-6,TNF-α水平明顯降低.而IL-2治療前顯著降低,治療後逐漸迴升(P<0.01);血清IL-6、TNF-α水平與FT3、FT4呈明顯正相關(P<0.05),而IL-2與FT3、FT4明顯負相關.結論131I治療Graves’病不僅可以安全有效地控製甲亢癥狀且可改善自身免疫紊亂,多種細胞因子的變化和131I治療的效果有關.
목적통과대131I치료전후Graves’병환자혈청IL-2、IL-6화TNF-α세포인자수평적비교,탐토세포인자여Graves병발생、발전적내재련계.방법방사면역분석법검측45례접수131I치료적GD환자치료전후60d외주혈청IL-2、IL-6화TNF-α농도변화,분석기여혈청갑상선격소수평적상관성분석.GD환자치료전혈청IL-6,TNF-α수평현저고우대조조(P<0.01),131I치료후IL-6,TNF-α수평명현강저.이IL-2치료전현저강저,치료후축점회승(P<0.01);혈청IL-6、TNF-α수평여FT3、FT4정명현정상관(P<0.05),이IL-2여FT3、FT4명현부상관.결론131I치료Graves’병불부가이안전유효지공제갑항증상차가개선자신면역문란,다충세포인자적변화화131I치료적효과유관.
Objective To study the changes of serum cytokine levels in patients with Graves disease (GD) before and after treated with iodine-131. Methods Using the method radoimmunoassay, the serum levels of interleukin-2 (IL-2), interleukin-6(IL-6) and TNF of Graves disease 45 patients before and after treated with iodine-131 and 30 control subjects were measured. Results The levels of IL-6, TNF-αof GD patients were significantly higher than that of the control group (P<0.01), the serum level of IL-2 of GD patients was significantly lower than that in the control subjects (P<0.01). The serum level of IL-6, TNF-αpositively correlated with FT3, FT4 (P<0.05), but IL-2 negatively correlated with FT3, FT4. Conclusions Cytokines play certain roles in the progressing of GD. Successful iodine 131 therapies would effectively suppress the immune status in Graves disease patients.